51
|
Vattai A, TL V, Schmoeckel E, Kuhn C, Mayr D, Mahner S, Jeschke U, Trillsch F. Trace amine-associated receptor 1 (TAAR1) als positiver prognostischer Marker für das epitheliale Ovarialkarzinom. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - Vogelsang TL
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - E Schmoeckel
- Pathologisches Institut, Medizinische Fakultät, LMU München
| | - C Kuhn
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - D Mayr
- Pathologisches Institut, Medizinische Fakultät, LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
- Klinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität Augsburg
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| |
Collapse
|
52
|
Beyer S, Fangfang C, Meister S, Czogalla B, Kolben TM, Hester A, Burges A, Trillsch F, Schmoeckel E, Mayr D, Mayerhofer A, Mahner S, Jeschke U, Kolben T. Sirtuin1 expression and survival in endometrial and clear-cell uterine cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - C Fangfang
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - B Czogalla
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - TM Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Hester
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - A Mayerhofer
- Biomedizinisches Zentrum München (BMC), Zellbioloige, Anatomie III, LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
53
|
Berger L, Kolben T, Meister S, Kolben TM, Schmoeckel E, Mayr D, Mahner S, Jeschke U, Ditsch N, Beyer S. Expression of H3K4me3 and H3K9ac in breast cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- L Berger
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - TM Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - N Ditsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
54
|
Mannewitz M, Kolben T, Meister S, Kolben T, Schmoeckel E, Mayr D, Anz D, Perleberg C, Burges A, Trillsch F, Vattai A, Corradini S, Czogalla B, Mahner S, Jeschke U, Beyer S. Regulatory T-cells as a potential target to overcome immune evasion in endometrial cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- M Mannewitz
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T.M Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - D Anz
- Arbeitsgruppe Immunregulation, Klinische Pharmakologie, Medizinische Klinik II, Klinikum der LMU München
| | - C Perleberg
- Arbeitsgruppe Immunregulation, Klinische Pharmakologie, Medizinische Klinik II, Klinikum der LMU München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Corradini
- Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Klinikum der LMU München
| | - B Czogalla
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
55
|
Liao Y, Badmann S, Kaltofen T, Mayr D, Schmoeckel E, Deuster E, Mannewitz M, Landgrebe S, Kolben T, Hester A, Beyer S, Burges A, Mahner S, Jeschke U, Trillsch F, Czogalla B. 851P PLA2G7/PAF-AH as protective factor and potential negative regulator of the Wnt signaling pathway in BRCA1 mutant ovarian cancer. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
56
|
Beilner D, Kuhn C, Kost BP, Jückstock J, Mayr D, Schmoeckel E, Dannecker C, Mahner S, Jeschke U, Heidegger HH. Lysine-specific histone demethylase 1A (LSD1) in cervical cancer. J Cancer Res Clin Oncol 2020; 146:2843-2850. [PMID: 32725356 PMCID: PMC7519903 DOI: 10.1007/s00432-020-03338-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2020] [Accepted: 07/23/2020] [Indexed: 12/27/2022]
Abstract
Purpose Demethylation of DNA through enzymes like LSD1 showed a crucial impact on different kind of cancers. Epigenetic modifications in cervical cancer are still not fully investigated nevertheless of high interest for a therapeutic use. Methods Tumor samples of 250 cervical cancer patients were immunochemically stained and evaluated based on Immunoreactive Score. Results were statistically analyzed for clinical and pathological parameters. Results Our patient collective showed a disadvantage for 10-year survival for patients with a strong expression of LSD1 in the cytoplasm of cervical cancer cells. The results of the correlational analysis further revealed a negative correlation of LSD1 to G-protein coupled estrogen receptor (GPER). Conclusions Epigenetic changes through enzymes like LSD1 may also be of interest for patients with cervical cancer. A combined therapy with other proteins relayed to cervical cancer like GPER might be of interest for future investigations.
Collapse
Affiliation(s)
- Daniel Beilner
- Department of Obstetrics and Gynaecology, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany
| | - Christina Kuhn
- Department of Obstetrics and Gynaecology, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany
| | - Bernd P Kost
- Department of Obstetrics and Gynaecology, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany
| | - Julia Jückstock
- Department of Obstetrics and Gynaecology, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany
| | - Doris Mayr
- Department of Pathology, LMU Munich, Thalkirchner Str. 56, 80337, Munich, Germany
| | - Elisa Schmoeckel
- Department of Pathology, LMU Munich, Thalkirchner Str. 56, 80337, Munich, Germany
| | - Christian Dannecker
- Department of Obstetrics and Gynaecology, University Hospital Augsburg, Stenglinstr. 2, 86156, Augsburg, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynaecology, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany
| | - Udo Jeschke
- Department of Obstetrics and Gynaecology, LMU Munich, Marchioninistraße 15, 81377, Munich, Germany. .,Department of Obstetrics and Gynaecology, University Hospital Augsburg, Stenglinstr. 2, 86156, Augsburg, Germany.
| | | |
Collapse
|
57
|
Mannewitz M, Kolben T, Meister S, Kolben TM, Schmoeckel E, Mayr D, Anz D, Perleberg C, Burges A, Trillsch F, Vattai A, Czogalla B, Corradini S, Mahner S, Jeschke U, Beyer S. Einfluss von Monozyten- und Makrophagen-sezerniertem CCL22 auf das Endometriumkarzinom. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1713969] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- M Mannewitz
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T M Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - D Anz
- Arbeitsgruppe Immunregulation (CIPS-M), Klinische Pharmakologie, Medizinische Klinik II, Klinikum der LMU München
| | - C Perleberg
- Arbeitsgruppe Immunregulation (CIPS-M), Klinische Pharmakologie, Medizinische Klinik II, Klinikum der LMU München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - B Czogalla
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Corradini
- Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Augsburg
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
58
|
Wehrmann M, Beyer S, Meister S, Kolben TM, Schmoeckel E, Mayr D, Burges A, Trillsch F, Vattai A, Hester A, Corradini S, Mahner S, Jeschke U, Kolben T. Galektin 8 und Galektin 9 als Prognostische Faktoren im Zervix-Karzinom. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1713966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- M Wehrmann
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T M Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Hester
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Corradini
- Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Augsburg
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
59
|
Kremer N, Vattai A, Schmoeckel E, Meister S, Beyer S, Czogalla B, Fürst S, Mahner S, Corradini S, Jeschke U, Kolben T, Kolben TM. Rolle der Makrophagendifferenzierung und -interaktion mit regulatorischen T-Zellen bei der Progression und Regression der HPV-induzierten Zervixdysplasie. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1713971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- N Kremer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - E Schmoeckel
- Pathologisches Institut, Medizinische Fakultät, LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - B Czogalla
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - S Fürst
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - S Corradini
- Klinik für Strahlentherapie, Klinikum der Universität München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
- Klinik und für Frauenheilkunde und Geburtshilfe, Klinikum der Universität Augsburg
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - T M Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| |
Collapse
|
60
|
Berger L, Kolben T, Meister S, Kolben TM, Schmoeckel E, Mayr D, Mahner S, Jeschke U, Ditsch N, Beyer S. Expression von H3K4me3 und H3K9ac in Brustkrebs. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1713965] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- L Berger
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T M Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - N Ditsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
61
|
Mannewitz M, Beyer S, Meister S, Kolben TM, Schmoeckel E, Mayr D, Anz D, Perleberg C, Burges A, Trillsch F, Vattai A, Czogalla B, Corradini S, Mahner S, Jeschke U, Kolben T. Regulatorische T-Zellen als potentielles Target zur Überwindung der Immunevasion bei Endometriumkarzinomen. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1713968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- M Mannewitz
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T M Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - D Anz
- Arbeitsgruppe Immunregulation (CIPS-M), Klinische Pharmakologie, Medizinische Klinik II, Klinikum der LMU München
| | - C Perleberg
- Arbeitsgruppe Immunregulation (CIPS-M), Klinische Pharmakologie, Medizinische Klinik II, Klinikum der LMU München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - B Czogalla
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Corradini
- Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Augsburg
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
62
|
Wehrmann M, Kolben T, Meister S, Kolben TM, Schmoeckel E, Mayr D, Burges A, Trillsch F, Vattai A, Hester A, Corradini S, Mahner S, Jeschke U, Beyer S. Gal-8, Gal-9, H3K9ac, H3K4me3 und der Glukokortikoidrezeptor als prognostische Marker im Endometriumkarzinom. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1713967] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- M Wehrmann
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - T M Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - E Schmoeckel
- Pathologisches Institut, Klinikum der LMU München
| | - D Mayr
- Pathologisches Institut, Klinikum der LMU München
| | - A Burges
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - F Trillsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - A Hester
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - S Corradini
- Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Augsburg
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg
| | - S Beyer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der LMU München
| |
Collapse
|
63
|
Vogelsang TLR, Schmoeckel E, Kuhn C, Blankenstein T, Temelkov M, Heidegger H, Kolben TM, Kolben T, Mahner S, Mayr D, Jeschke U, Vattai A. Die Regulation der LCoR und RIP140 Expression in zervikaler intraepithelialer Neoplasie (CIN) und deren Korrelation mit CIN-Progress und Dedifferenzierung. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1713973] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- T LR Vogelsang
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - E Schmoeckel
- Pathologisches Institut, Medizinische Fakultät, LMU München
| | - C Kuhn
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - T Blankenstein
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - M Temelkov
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - H Heidegger
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - T M Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| | - D Mayr
- Pathologisches Institut, Medizinische Fakultät, LMU München
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
- Klinik und für Frauenheilkunde und Geburtshilfe, Klinikum der Universität Augsburg
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München
| |
Collapse
|
64
|
Eppich S, Kuhn C, Schmoeckel E, Mayr D, Mahner S, Jeschke U, Gallwas J, Heidegger HH. MSX1-A Potential Marker for Uterus-Preserving Therapy of Endometrial Carcinomas. Int J Mol Sci 2020; 21:ijms21124529. [PMID: 32630554 PMCID: PMC7350265 DOI: 10.3390/ijms21124529] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2020] [Revised: 06/17/2020] [Accepted: 06/22/2020] [Indexed: 12/28/2022] Open
Abstract
Prognostic factors are of great interest in patients with endometrial cancer. One potential factor could be the protein MSX1, a transcription repressor, that has an inhibitory effect on the cell cycle. For this study, endometrioid endometrial carcinomas (n = 53), clear cell endometrial carcinomas (n = 6), endometrioid ovarian carcinomas (n = 19), and clear cell ovarian carcinomas (n = 11) were immunochemically stained for the protein MSX1 and evaluated using the immunoreactive score (IRS). A significant stronger expression of MSX1 was found in endometrioid endometrial carcinomas (p < 0.001), in grading 2 (moderate differentiation) (p = 0.001), and in tumor material of patients with no involvement of lymph nodes (p = 0.031). Correlations were found between MSX1 expression and the expression of β-Catenin, p21, p53, and the steroid receptors ERα, ERβ, PRα, and PRβ. A significant (p = 0.023) better survival for patients with an MSX1 expression in more than 10% of the tumor cells was observed for endometrioid endometrial carcinomas (21.3 years median survival (MSX1-positive) versus 17.3 years (MSX1-negative)). Although there is evidence that MSX1 expression correlates with improved long-term survival, further studies are necessary to evaluate if MSX1 can be used as a prognostic marker.
Collapse
Affiliation(s)
- Simon Eppich
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU), Marchioninistraße 15, 81377 Munich, Germany; (S.E.); (C.K.); (S.M.); (J.G.); (H.H.H.)
| | - Christina Kuhn
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU), Marchioninistraße 15, 81377 Munich, Germany; (S.E.); (C.K.); (S.M.); (J.G.); (H.H.H.)
| | - Elisa Schmoeckel
- Department of Pathology, LMU Munich, Thalkirchner Str. 56, 80337 Munich, Germany; (E.S.); (D.M.)
| | - Doris Mayr
- Department of Pathology, LMU Munich, Thalkirchner Str. 56, 80337 Munich, Germany; (E.S.); (D.M.)
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU), Marchioninistraße 15, 81377 Munich, Germany; (S.E.); (C.K.); (S.M.); (J.G.); (H.H.H.)
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU), Marchioninistraße 15, 81377 Munich, Germany; (S.E.); (C.K.); (S.M.); (J.G.); (H.H.H.)
- Department of Obstetrics and Gynecology, University Hospital Augsburg, Stenglinstr. 2, 86156 Augsburg, Germany
- Correspondence: ; Tel.: +49-89-4400-54240
| | - Julia Gallwas
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU), Marchioninistraße 15, 81377 Munich, Germany; (S.E.); (C.K.); (S.M.); (J.G.); (H.H.H.)
- Department of Gynecology and Obstetrics, Georg August University Goettingen, University Medicine, 37075 Goettingen, Germany
| | - Helene Hildegard Heidegger
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU), Marchioninistraße 15, 81377 Munich, Germany; (S.E.); (C.K.); (S.M.); (J.G.); (H.H.H.)
| |
Collapse
|
65
|
Ditsch N, Heublein S, Jeschke U, Sattler C, Kuhn C, Hester A, Czogalla B, Trillsch F, Mahner S, Engel J, Mayr D, Schmoeckel E. Cytoplasmic versus nuclear THR alpha expression determines survival of ovarian cancer patients. J Cancer Res Clin Oncol 2020; 146:1923-1932. [PMID: 32533406 PMCID: PMC7324415 DOI: 10.1007/s00432-020-03241-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2020] [Accepted: 05/01/2020] [Indexed: 12/16/2022]
Abstract
Purpose
Thyroid hormone receptors (THR) have manifold functions and are involved in the carcinogenesis of several tumor types. Within this study, we aimed to investigate the expression pattern (nuclear versus cytoplasmic) of the THR alpha and its impact on patients survival in ovarian cancer (OvCa). Methods The presence of the thyroid hormone receptors THRα, THRα1 and − 2 was investigated in 156 ovarian cancer samples using immunohistochemistry (IHC) using semi-quantitative immunoreactivity (IR) scores and correlated with clinical, pathological data, subtype of ovarian cancer, clinical data, staining of 20 already described OvCa marker proteins and overall survival (OS). Results Among all subtypes of OvCa, clear cell carcinomas showed the highest THRα expression. Furthermore, nuclear THRα was associated with a reduced survival in this subtype. However, nuclear expressed THRα1 turned out to be a positive prognosticator for all subtypes of OvCa patients. Nuclear THRα2 is a positive prognosticator for OvCa patients of the serous subtype. In contrast, cytoplasmic expression THRα2 was associated with a reduced OS in all subtypes of OvCa patients; while, cytoplasmic expression of THRα1 is associated with reduced OS in mucinous OvCa patients only. In addition, THRα expression correlates with gonadotropin receptors, steroid hormone receptors, TA-MUC1 and glycodelin. Conclusion Depending on nuclear or cytoplasmic expression, our study shows that THRα and its isoforms 1 and 2 provide different prognostic information for ovarian cancer patients. Further investigations should analyze if THRs may represent new endocrine targets for the treatment of ovarian cancer. Electronic supplementary material The online version of this article (10.1007/s00432-020-03241-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Nina Ditsch
- Department of Obstetrics and Gynecology, LMU Munich, University Hospital, Marchioninistr. 15, 81377 Munich, Germany
- Department of Obstetrics and Gynecology, University Hospital Augsburg, Stenglinstrasse 2, 86156 Augsburg, Germany
| | - Sabine Heublein
- Department of Obstetrics and Gynecology, LMU Munich, University Hospital, Marchioninistr. 15, 81377 Munich, Germany
- Department of Obstetrics and Gynecology, Heidelberg University Hospital, Ruprecht-Karls-University of Heidelberg, 69120 Heidelberg, Germany
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, LMU Munich, University Hospital, Marchioninistr. 15, 81377 Munich, Germany
- Department of Obstetrics and Gynecology, University Hospital Augsburg, Stenglinstrasse 2, 86156 Augsburg, Germany
| | - Cornelia Sattler
- Department of Obstetrics and Gynecology, LMU Munich, University Hospital, Marchioninistr. 15, 81377 Munich, Germany
| | - Christina Kuhn
- Department of Obstetrics and Gynecology, LMU Munich, University Hospital, Marchioninistr. 15, 81377 Munich, Germany
| | - Anna Hester
- Department of Obstetrics and Gynecology, LMU Munich, University Hospital, Marchioninistr. 15, 81377 Munich, Germany
| | - Bastian Czogalla
- Department of Obstetrics and Gynecology, LMU Munich, University Hospital, Marchioninistr. 15, 81377 Munich, Germany
| | - Fabian Trillsch
- Department of Obstetrics and Gynecology, LMU Munich, University Hospital, Marchioninistr. 15, 81377 Munich, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynecology, LMU Munich, University Hospital, Marchioninistr. 15, 81377 Munich, Germany
| | - Jutta Engel
- Munich Cancer Registry (MCR), Bavarian Cancer Registry—Regional Centre Munich (LGL), Institute for Medical Information Processing, Biometry and Epidemiology (IBE), Ludwig-Maximilians-University (LMU), Munich, Germany
| | - Doris Mayr
- Department of Pathology, LMU Munich, Thalkirchner Str. 36, 80337 Munich, Germany
| | - Elisa Schmoeckel
- Department of Pathology, LMU Munich, Thalkirchner Str. 36, 80337 Munich, Germany
| |
Collapse
|
66
|
Löb S, Vattai A, Kuhn C, Schmoeckel E, Mahner S, Wöckel A, Kolben T, Szekeres-Bartho J, Jeschke U, Vilsmaier T. Spliceosome protein EFTUD2 is upregulated in the trophoblast of spontaneous miscarriage and hydatidiform mole. J Reprod Immunol 2020; 140:103149. [PMID: 32447180 DOI: 10.1016/j.jri.2020.103149] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2020] [Revised: 04/03/2020] [Accepted: 05/11/2020] [Indexed: 01/22/2023]
Abstract
BACKGROUND Elongation factor Tu GTP binding domain containing 2 (EFTUD2) is an alternative splicing factor that modulates cell differentiation and activation processes. EFTUD2 is known to modulate immune responses and mutation of the EFTUD2-gene lead to fetal malformation. Little is known about its expression and role in normal and disturbed first trimester pregnancy. PATIENTS AND METHODS We investigated the expression of EFTUD2 in placental tissue obtained from patients with normal (n = 14), spontaneous miscarriage (n = 15) and molar (n = 14) pregnancy by immunohistochemistry. The expression of EFTUD2 was correlated on the protein level with known immune modulatory proteins like pregnancy zone protein (PZP) and in addition with human chorionic gonadotropin (hCG). Furthermore, we analysed the EFTUD2 and PZP expression in vitro after stimulation of the chorioncarcinoma cell line JEG-3 with hCG. RESULTS EFTUD2 is significantly upregulated in the syncytiotrophoblast of spontaneous miscarriage (p = 0.003) and molar pregnancy (p = 0.003) compared to week of gestation-adjusted normal first trimester placentas. PZP is negatively correlated (p = 0.021) to EFTUD2 in the syncytiotrophoblast and is therefore significantly downregulated in miscarriage (p = 0.028) and mole pregnancy (p = 0.006). In addition, hCG is positively correlated to EFTUD2 in mole pregnancy. The addition of hCG to chorioncarcinoma cell lines JEG-3 in vitro stimulated EFTUD2 expression in these cells (p = 0.027). CONCLUSION Regulation of alternative splicing seems crucial for a successful ongoing pregnancy. The up-regulated elongation factor EFTUD2 may have a critical role in miscarriage.
Collapse
Affiliation(s)
- Sanja Löb
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Maistrasse 11, 80337,Munich, Germany; Department of Obstetrics and Gynecology, University Hospital, University of Wuerzburg, Josef-Schneider-Str. 4, 97080,Würzburg, Germany
| | - Aurelia Vattai
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Maistrasse 11, 80337,Munich, Germany
| | - Christina Kuhn
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Maistrasse 11, 80337,Munich, Germany
| | - Elisa Schmoeckel
- Department of Pathology, LMU Munich, Marchioninistr. 27, 81377,Munich, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Maistrasse 11, 80337,Munich, Germany
| | - Achim Wöckel
- Department of Obstetrics and Gynecology, University Hospital, University of Wuerzburg, Josef-Schneider-Str. 4, 97080,Würzburg, Germany
| | - Thomas Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Maistrasse 11, 80337,Munich, Germany
| | | | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Maistrasse 11, 80337,Munich, Germany; Department of Obstetrics and Gynecology, University Hospital Augsburg, Stenglinstrasse 2, 86156,Augsburg, Germany.
| | - Theresa Vilsmaier
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Maistrasse 11, 80337,Munich, Germany
| |
Collapse
|
67
|
Eggersmann TK, Baumeister P, Kumbrink J, Mayr D, Schmoeckel E, Thaler CJ, Dannecker C, Jeschke U, Nagler T, Mahner S, Sharaf K, Gallwas JKS. Oropharyngeal HPV Detection Techniques in HPV-associated Head and Neck Cancer Patients. Anticancer Res 2020; 40:2117-2123. [PMID: 32234904 DOI: 10.21873/anticanres.14170] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2020] [Revised: 03/09/2020] [Accepted: 03/11/2020] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM The incidence of human papilloma virus (HPV)-related head and neck squamous cell carcinoma (HNSCC) has been increasing in the last decades. Analysis of oral brushing or rinsing samples for screening or stratification could potentially improve screening and prevention. PATIENTS AND METHODS Oral brushes and mouthwashes were taken from 20 patients with HPV-associated HNSCC before definite therapy. HPV genotyping was performed for the detection of 14 high-risk HPV subtypes and correlated to DNA isolated from tumor tissue. RESULTS Ten of 20 patients were tested HPV positive by using either method. There was a significant correlation between macroscopic visibility of tumor and positive HPV detection (p<0.001) and HPV detection and tumor size (p<0.001). HPV was detected in all macroscopically visible tumors. Half of the HPV cases who had macroscopically invisible tumors were missed by both methods. CONCLUSION Both techniques are limited in the detection of macroscopically non-visible and small tumors. Therefore, the application of these techniques for screening or diagnosis of HNSCC is not recommended.
Collapse
Affiliation(s)
- Tanja K Eggersmann
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Philipp Baumeister
- Department of Otorhinolaryngology, University Hospital, LMU Munich, Munich, Germany
| | - Jorg Kumbrink
- Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Doris Mayr
- Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Elisa Schmoeckel
- Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany
| | - Christian J Thaler
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Christian Dannecker
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.,Department for Gynecology and Obstetrics, University of Augsburg, Augsburg, Germany
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.,Department for Gynecology and Obstetrics, University of Augsburg, Augsburg, Germany
| | - Thomas Nagler
- Mathematical Institute, Leiden University, Leiden, the Netherlands
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Kariem Sharaf
- Department of Otorhinolaryngology, University Hospital, LMU Munich, Munich, Germany
| | - Julia K S Gallwas
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.,Department of Gynecology and Obstetrics, Georg-August-University Goettingen, Goettingen, Germany
| |
Collapse
|
68
|
Mittlmeier LM, Unterrainer M, Todica A, Clevert DA, Cyran CC, Schmoeckel E, Rodler S, Bartenstein P, Stief CG, Ilhan H, Staehler M. Advanced Molecular Imaging in Histologically Verified Metanephric Adenoma. Urology 2020; 140:e10-e11. [PMID: 32171695 DOI: 10.1016/j.urology.2020.02.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2019] [Revised: 02/22/2020] [Accepted: 02/25/2020] [Indexed: 10/24/2022]
Abstract
Metanephric adenoma (MA) describes a rare renal tumor and is generally considered a benign lesion. However, there are cases with regional lymphogenic and distant metastases. Noninvasive diagnosis of MA using conventional imaging remains challenging. Here, we describe a case of histologically verified MA with additional advanced molecular imaging consisting of 18F-PSMA-1007 PET/CT, 99mTc-Sestamibi SPECT and contrast-enhanced ultrasound.
Collapse
Affiliation(s)
- L M Mittlmeier
- Department of Urology, University Hospital, LMU Munich, Munich, Germany; Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany
| | - M Unterrainer
- Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany
| | - A Todica
- Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany
| | - D A Clevert
- Department of Radiology, University Hospital, LMU Munich, Munich, Germany
| | - C C Cyran
- Department of Radiology, University Hospital, LMU Munich, Munich, Germany
| | - E Schmoeckel
- Institute of Pathology, University Hospital, LMU Munich, Munich, Germany
| | - S Rodler
- Department of Urology, University Hospital, LMU Munich, Munich, Germany
| | - P Bartenstein
- Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany
| | - C G Stief
- Department of Urology, University Hospital, LMU Munich, Munich, Germany
| | - H Ilhan
- Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany
| | - M Staehler
- Department of Urology, University Hospital, LMU Munich, Munich, Germany.
| |
Collapse
|
69
|
Vogelsang TLR, Schmoeckel E, Kuhn C, Blankenstein T, Temelkov M, Heidegger H, Kolben TM, Kolben T, Mahner S, Mayr D, Jeschke U, Vattai A. Regulation of LCoR and RIP140 expression in cervical intraepithelial neoplasia and correlation with CIN progression and dedifferentiation. J Cancer Res Clin Oncol 2020; 146:1847-1855. [PMID: 32157438 PMCID: PMC7256097 DOI: 10.1007/s00432-020-03178-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2020] [Accepted: 03/03/2020] [Indexed: 02/07/2023]
Abstract
Purpose Ligand-dependent corepressor (LCoR) and receptor-interacting protein 140 (RIP140/NRIP1) play an important role in the regulation of multiple oncogenic signaling pathways and the development of cancer. LCoR and RIP140 form a nuclear complex in breast cancer cells and are of prognostic value in further prostate and cervical cancer. The purpose of this study was to analyze the regulation of these proteins in the development of cervical intraepithelial neoplasia (CIN I–III). Methods Immunohistochemical analysis was obtained to quantify RIP140 and LCoR expression in formalin-fixed paraffin embedded tissue sections of cervical intraepithelial neoplasia samples. Tissue (n = 94) was collected from patients treated in the Department of Gynecology and Obstetrics, Ludwig-Maximilians-University of Munich, Germany, between 2002 and 2014. Correlations of expression levels with clinical outcome were carried out to assess for prognostic relevance in patients with CIN2 progression. Kruskal–Wallis test and Mann–Whitney U test were used for data analysis. Results Nuclear LCoR overexpression correlates significantly with CIN II progression. Nuclear RIP140 expression significantly increases and nuclear LCoR expression decreases with higher grading of cervical intraepithelial neoplasia. Cytoplasmic RIP140 expression is significantly higher in CIN III than in CIN I or CIN II. Conclusion A decrease of nuclear LCoR expression in line with an increase of dedifferentiation of CIN can be observed. Nuclear LCoR overexpression correlates with CIN II progression indicating a prognostic value of LCoR in cervical intraepithelial neoplasia. Nuclear and cytoplasmic RIP140 expression increases significantly with higher grading of cervical intraepithelial neoplasia underlining its potential role in the development of pre-cancerous lesions. These findings support the relevance of LCoR and RIP140 in the tumorigenesis indicating a possible role of LCoR and RIP140 as targets for novel therapeutic approaches in cervical intraepithelial neoplasia and cervical cancer.
Collapse
Affiliation(s)
- Tilman L R Vogelsang
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80337, Munich, Germany
| | - Elisa Schmoeckel
- Institute of Pathology, Faculty of Medicine, LMU Munich, 80337, Munich, Germany
| | - Christina Kuhn
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80337, Munich, Germany
| | - Thomas Blankenstein
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80337, Munich, Germany
| | - Mina Temelkov
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80337, Munich, Germany
| | - Helene Heidegger
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80337, Munich, Germany
| | - Theresa Maria Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80337, Munich, Germany
| | - Thomas Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80337, Munich, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80337, Munich, Germany
| | - Doris Mayr
- Institute of Pathology, Faculty of Medicine, LMU Munich, 80337, Munich, Germany
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80337, Munich, Germany. .,Department of Obstetrics and Gynecology, University Hospital Augsburg, 86156, Augsburg, Germany.
| | - Aurelia Vattai
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80337, Munich, Germany
| |
Collapse
|
70
|
Czogalla B, Pham D, Trillsch F, Rottmann M, Gallwas J, Burges A, Mahner S, Kirchner T, Jeschke U, Mayr D, Schmoeckel E. PD-L1 expression and survival in p16-negative and -positive squamous cell carcinomas of the vulva. J Cancer Res Clin Oncol 2020; 146:569-577. [PMID: 32025868 PMCID: PMC7040065 DOI: 10.1007/s00432-020-03126-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2019] [Accepted: 01/02/2020] [Indexed: 12/12/2022]
Abstract
AIM Programmed death-ligand 1 (PD-L1) has become a widely used predictive biomarker for therapy with checkpoint inhibitors in a variety of cancers. Here, we studied the expression of PD-L1 in squamous cell carcinomas of the vulva (SCCV) with regard to HPV status via its surrogate marker p16. Additionally, the status of PD-L1 and p16 were analyzed for prognostic information and potential correlation to tumor-infiltrating lymphocytes (TILs). METHODS PD-L1 was analyzed in 128 cases of SCCV using the tumor proportion score (TPS), the immune cell score (ICS) and the combined positive score (CPS). Cases were immunostained for p16 and analyzed for stromal TILs. PD-L1, p16, and TILs were compared to clinico-pathological parameters and patient's survival. RESULTS TPS ≥ 50% and CPS ≥ 50 were correlated to a worse grading (p = 0.028 and p = 0.031), but not to FIGO-stage. CPS ≥ 50 was associated to a worse prognosis with overall survival (p = 0.021) but was not correlated to the progression-free survival. P16-positivity was correlated to a longer progression-free survival (p = 0.006) and overall survival (p = 0.023). PD-L1 expression was independent from p16 status. TILs ≥ 50% were present in 24% of the cases and were strongly correlated to PD-L1 (TPS p = 0.02, ICS p < 0.001, CPS p = 0.001). CONCLUSION Our data demonstrate that PD-L1 expression is frequent in SCCV and independent from p16 status. High PD-L1 expression was associated with an unfavorable outcome whereas p16-positivity turned out to be an independent positive prognostic factor.
Collapse
Affiliation(s)
- Bastian Czogalla
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU), Munich, Germany
| | - Deborah Pham
- Institute of Pathology, Ludwig Maximilians University (LMU), Munich, Germany
| | - Fabian Trillsch
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU), Munich, Germany
| | - Miriam Rottmann
- Munich Cancer Registry, Bavarian Cancer Registry-Regional Centre Munich (LGL) at the University Hospital of Munich, Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig Maximilians University (LMU), Munich, Germany
| | - Julia Gallwas
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU), Munich, Germany
| | - Alexander Burges
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU), Munich, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU), Munich, Germany
| | - Thomas Kirchner
- Institute of Pathology, Ludwig Maximilians University (LMU), Munich, Germany
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital, Ludwig Maximilians University (LMU), Munich, Germany
| | - Doris Mayr
- Institute of Pathology, Ludwig Maximilians University (LMU), Munich, Germany
| | - Elisa Schmoeckel
- Institute of Pathology, Ludwig Maximilians University (LMU), Munich, Germany.
| |
Collapse
|
71
|
Wang Q, Schmoeckel E, Kost BP, Kuhn C, Vattai A, Vilsmaier T, Mahner S, Mayr D, Jeschke U, Heidegger HH. Higher CCL22+ Cell Infiltration is Associated with Poor Prognosis in Cervical Cancer Patients. Cancers (Basel) 2019; 11:cancers11122004. [PMID: 31842422 PMCID: PMC6966573 DOI: 10.3390/cancers11122004] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2019] [Revised: 12/09/2019] [Accepted: 12/11/2019] [Indexed: 12/16/2022] Open
Abstract
The chemokine CCL22 recruits regulatory T (T-reg) cells into tumor tissues and is expressed in many human tumors. However, the prognostic role of CCL22 in cervical cancer (CC) has not been determined. This study retrospectively analyzed the clinical significance of the expression of CCL22 and FOXP3 in 230 cervical cancer patients. Immunohistochemical staining analyses of CCL22 and FOXP3 were performed with a tissue microarray. Double immunofluorescence staining, cell coculture, and ELISA were used to determine CCL22 expressing cells and mechanisms. The higher number of infiltrating CCL22+ cells (CCL22high) group was associated with lymph node metastasis (p = 0.004), Fédération Internationale de Gynécologie et d’Obstétrique (FIGO) stages (p = 0.010), therapeutic strategies (p = 0.007), and survival status (p = 0.002). The number of infiltrating CCL22+ cells was positively correlated with that of infiltrating FOXP3+ cells (r = 0.210, p = 0.001). The CCL22high group had a lower overall survival rate (OS), compared to the CCL22low group (p = 0.001). However, no significant differences in progression free survival (PFS) were noted between the two groups. CCL22high was an independent predictor of shorter OS (HR, 4.985; p = 0.0001). The OS of the combination group CCL22highFOXP3high was significantly lower than that of the combination group CCL22lowFOXP3low regardless of the FIGO stage and disease subtype. CCL22highFOXP3high was an independent indictor of shorter OS (HR, 5.284; p = 0.009). The PFS of group CCL22highFOXP3high was significantly lower than that of group CCL22lowFOXP3low in cervical adenocarcinoma, but CCL22highFOXP3high was not an independent indicator (HR, 3.018; p = 0.068). CCL22 was primarily expressed in M2-like macrophages in CC and induced by cervical cancer cells. The findings of our study indicate that cervical cancer patients with elevated CCL22+ infiltrating cells require more aggressive treatment. Moreover, the results provide a basis for subsequent, comprehensive studies to advance the design of immunotherapy for cervical cancer.
Collapse
Affiliation(s)
- Qun Wang
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80377 Munich, Germany; (Q.W.); (B.P.K.); (C.K.); (A.V.); (T.V.); (S.M.); (H.H.H.)
| | - Elisa Schmoeckel
- Department of Pathology, LMU Munich, 80377 Munich, Germany; (E.S.); (D.M.)
| | - Bernd P. Kost
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80377 Munich, Germany; (Q.W.); (B.P.K.); (C.K.); (A.V.); (T.V.); (S.M.); (H.H.H.)
| | - Christina Kuhn
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80377 Munich, Germany; (Q.W.); (B.P.K.); (C.K.); (A.V.); (T.V.); (S.M.); (H.H.H.)
| | - Aurelia Vattai
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80377 Munich, Germany; (Q.W.); (B.P.K.); (C.K.); (A.V.); (T.V.); (S.M.); (H.H.H.)
| | - Theresa Vilsmaier
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80377 Munich, Germany; (Q.W.); (B.P.K.); (C.K.); (A.V.); (T.V.); (S.M.); (H.H.H.)
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80377 Munich, Germany; (Q.W.); (B.P.K.); (C.K.); (A.V.); (T.V.); (S.M.); (H.H.H.)
| | - Doris Mayr
- Department of Pathology, LMU Munich, 80377 Munich, Germany; (E.S.); (D.M.)
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80377 Munich, Germany; (Q.W.); (B.P.K.); (C.K.); (A.V.); (T.V.); (S.M.); (H.H.H.)
- Correspondence:
| | - Helene Hildegard Heidegger
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80377 Munich, Germany; (Q.W.); (B.P.K.); (C.K.); (A.V.); (T.V.); (S.M.); (H.H.H.)
| |
Collapse
|
72
|
Czogalla B, Kahaly M, Mayr D, Schmoeckel E, Niesler B, Hester A, Zeder-Göß C, Kolben T, Burges A, Mahner S, Jeschke U, Trillsch F. Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology. Cancer Manag Res 2019; 11:7673-7684. [PMID: 31616183 PMCID: PMC6699153 DOI: 10.2147/cmar.s210004] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2019] [Accepted: 06/27/2019] [Indexed: 12/18/2022] Open
Abstract
Purpose This study aimed to investigate the potential prognostic impact of nuclear factor erythroid 2-related factor 2 (NRF2) and progesterone receptor A (PRA)/progesterone receptor B (PRB) in ovarian cancer patients which might be the rationale for putative new treatment strategies. Patients and methods The presence of NRF2 and PRA/PRB was investigated in 156 ovarian cancer samples using immunohistochemistry (IHC). Staining of NRF2 and PRA/PRB was rated using the semi-quantitative immunoreactive score (IR score, Remmele’s score) and correlated to clinical and pathological data. NRF2 and PRA/PRB expression were compared with respect to the overall survival (OS). Results NRF2 staining was different in both, the cytoplasm and nucleus between the histological subtypes (p=0.001 and p=0.02, respectively). There was a significant difference in the PRA expression comparing all histological subtypes (p=0.02). Histological subtypes showed no significant differences in the PRB expression. A strong correlation of cytoplasmic NRF2 and PRA expression was detected (cc=0.247, p=0.003) as well as of cytoplasmic NRF2 and PRB expression (cc=0.25, p=0.003), confirmed by immunofluorescence double staining. Cytoplasmic NRF2 expression was associated with a longer OS (median 50.6 vs 32.5 months; p=0.1) as it was seen for PRA expression (median 63.4 vs 33.1 months; p=0.08), although not statistically significant. In addition, high PRB expression (median 80.4 vs 32.5 months; p=0.04) and concurrent expression of cytoplasmic NRF2 and PRA were associated with a significantly longer OS (median 109.7 vs 30.6 months; p=0.02). The same relationship was also noted for NRF2 and PRB with improved OS for patients expressing both cytoplasmic NRF2 and PRB (median 153.5 vs 30.6 months; p=0.009). Silencing of NFE2L2 induced higher mRNA expression of PGR in the cancer cell line OVCAR3 (p>0.05) confirming genetic interactions of NRF2 and PR. Conclusion In this study, the combination of cytoplasmic NRF2 and high PRA/PRB expression was demonstrated to be associated with improved overall survival in ovarian cancer patients. Further understanding of interactions within the NRF2/AKR1C1/PR pathway could open new additional therapeutic approaches.
Collapse
Affiliation(s)
- Bastian Czogalla
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Maja Kahaly
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Doris Mayr
- Faculty of Medicine, Institute of Pathology, Lmu Munich, Munich, Germany
| | - Elisa Schmoeckel
- Faculty of Medicine, Institute of Pathology, Lmu Munich, Munich, Germany
| | - Beate Niesler
- Department of Human Molecular Genetics, Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany
| | - Anna Hester
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Christine Zeder-Göß
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Thomas Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Alexander Burges
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Fabian Trillsch
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| |
Collapse
|
73
|
Kolben TM, Meister S, Rogatsch E, Vattai A, Hester A, Kuhn C, Schmoeckel E, Mahner S, Jeschke U, Kolben T. Die Expression von PPARγ in trophoblastärem Gewebe spontaner und habitueller Aborte im Vergleich zu gesunden Schwangerschaften. Geburtshilfe Frauenheilkd 2019. [DOI: 10.1055/s-0039-1693874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Affiliation(s)
- TM Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - S Meister
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - E Rogatsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - A Vattai
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - A Hester
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - C Kuhn
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - E Schmoeckel
- Pathologisches Institut, LMU München, München, Deutschland
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, LMU München, München, Deutschland
| |
Collapse
|
74
|
Heublein S, Page S, Mayr D, Schmoeckel E, Trillsch F, Marmé F, Mahner S, Jeschke U, Vattai A. Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer. Int J Mol Sci 2019; 20:ijms20020295. [PMID: 30642093 PMCID: PMC6359481 DOI: 10.3390/ijms20020295] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2018] [Revised: 12/17/2018] [Accepted: 12/24/2018] [Indexed: 12/20/2022] Open
Abstract
Anti-tumor efficacy of Gatipotuzumab, a therapeutic antibody targeting Tumor-Associated Mucin-1 (TA-MUC1), in relapsed ovarian cancer (OC) appeared to be rather heterogeneous. Whether adding a second anti-neoplastic drug may augment response towards Gatipotuzumab, has not been elucidated so far. Since it is known that anti-MUC1 antibodies may alter estrogen receptor activity in breast cancer, this potential interplay was investigated in OC. The correlation between TA-MUC1, estrogen receptors (ERs) and another 12 protein markers as well as their correlation with clinico-pathological parameters in 138 ovarian cancer cases was studied. Finally, Gatipotuzumab and 4-Hydroxy-TTamoxifen (4-OHT) as well as the combination of both was tested for its impact on cell viability in COV318, OV-90, OVCAR-3, and SKOV-3 cells. A strong positive correlation between TA-MUC1 and ERs was detected in OC tissue. Those cases missing ERs but staining positive for TA-MUC1 had significantly reduced overall survival. The combination of 4-OHT and Gatipotuzumab significantly reduced cell viability and was more effective than treatment with Gatipotuzumab alone. Co-stimulation with Gatipotuzumab enhanced the efficacy of 4-OHT in OVCAR-3 and SKOV-3. The data suggest an interplay of TA-MUC1 and ERs in OC. Whether the combination of Gatipotuzumab and TTamoxifen may enhance efficacy of either of the two drugs in vivo, or may even translate into a clinically relevant benefit over the respective monotherapies, remains to be investigated.
Collapse
Affiliation(s)
- Sabine Heublein
- Department of Obstetrics and Gynecology, Ludwig-Maximilians University of Munich, University Hospital, 81377 Munich, Germany.
- Department of Obstetrics and Gynecology, University of Heidelberg, 69117 Heidelberg, Germany.
| | - Sabina Page
- Department of Obstetrics and Gynecology, Ludwig-Maximilians University of Munich, University Hospital, 81377 Munich, Germany.
| | - Doris Mayr
- Department of Pathology, Ludwig-Maximilians University of Munich, 81377 Munich, Germany.
| | - Elisa Schmoeckel
- Department of Pathology, Ludwig-Maximilians University of Munich, 81377 Munich, Germany.
| | - Fabian Trillsch
- Department of Obstetrics and Gynecology, Ludwig-Maximilians University of Munich, University Hospital, 81377 Munich, Germany.
| | - Frederik Marmé
- Department of Obstetrics and Gynecology, University of Heidelberg, 69117 Heidelberg, Germany.
| | - Sven Mahner
- Department of Obstetrics and Gynecology, Ludwig-Maximilians University of Munich, University Hospital, 81377 Munich, Germany.
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, Ludwig-Maximilians University of Munich, University Hospital, 81377 Munich, Germany.
| | - Aurelia Vattai
- Department of Obstetrics and Gynecology, Ludwig-Maximilians University of Munich, University Hospital, 81377 Munich, Germany.
| |
Collapse
|
75
|
Czogalla B, Kahaly M, Mayr D, Schmoeckel E, Niesler B, Kolben T, Burges A, Mahner S, Jeschke U, Trillsch F. Interaction of ERα and NRF2 Impacts Survival in Ovarian Cancer Patients. Int J Mol Sci 2018; 20:ijms20010112. [PMID: 30597961 PMCID: PMC6337731 DOI: 10.3390/ijms20010112] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2018] [Revised: 12/19/2018] [Accepted: 12/21/2018] [Indexed: 11/16/2022] Open
Abstract
Nuclear factor erythroid 2-related factor 2 (NRF2) regulates cytoprotective antioxidant processes. In this study, the prognostic potential of NRF2 and its interactions with the estrogen receptor α (ERα) in ovarian cancer cells was investigated. NRF2 and ERα protein expression in ovarian cancer tissue was analyzed as well as mRNA expression of NRF2 (NFE2L2) and ERα (ESR1) in four ovarian cancer and one benign cell line. NFE2L2 silencing was carried out to evaluate a potential interplay between NRF2 and ERα. Cytoplasmic NRF2 expression as inactive form had significantly higher expression in patients with low-grade histology (p = 0.03). In the serous cancer subtype, high cytoplasmic NRF2 expression (overall survival (OS), median 50.6 vs. 29.3 months; p = 0.04) and high ERα expression (OS, median 74.5 vs. 27.1 months; p = 0.002) was associated with longer overall survival as well as combined expression of both inactive cytoplasmic NRF2 and ERα in the whole cohort (median 74.5 vs. 37.7 months; p = 0.04). Cytoplasmic NRF2 expression showed a positive correlation with ERα expression (p = 0.004). NFE2L2 was found to be highly expressed in the ovarian cancer cell lines OVCAR3, UWB1.289, and TOV112D. Compared with the benign cell line HOSEpiC, ESR1 expression was reduced in all ovary cancer cell lines (all p < 0.001). Silencing of NFE2L2 induced a higher mRNA expression of ESR1 in the NFE2L2 downregulated cancer cell lines OVCAR3 (p = 0.003) and ES2 (p < 0.001), confirming genetic interactions of NRF2 and ERα. In this study, both inactive cytoplasmic NRF2 and high ERα expression were demonstrated to be associated with improved survival in ovarian cancer patients. Further understanding of interactions within the estradiol⁻ERα⁻NRF2 pathway could better predict the impact of endocrine therapy in ovarian cancer.
Collapse
Affiliation(s)
- Bastian Czogalla
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany.
| | - Maja Kahaly
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany.
| | - Doris Mayr
- Institute of Pathology, Faculty of Medicine, 81377 LMU Munich, Germany.
| | - Elisa Schmoeckel
- Institute of Pathology, Faculty of Medicine, 81377 LMU Munich, Germany.
| | - Beate Niesler
- Institute of Human Genetics, Department of Human Molecular Genetics, University of Heidelberg, 69120 Heidelberg, Germany.
| | - Thomas Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany.
| | - Alexander Burges
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany.
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany.
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany.
| | - Fabian Trillsch
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany.
| |
Collapse
|
76
|
Kuehnemuth B, Piseddu I, Wiedemann GM, Lauseker M, Kuhn C, Hofmann S, Schmoeckel E, Endres S, Mayr D, Jeschke U, Anz D. CCL1 is a major regulatory T cell attracting factor in human breast cancer. BMC Cancer 2018; 18:1278. [PMID: 30572845 PMCID: PMC6302432 DOI: 10.1186/s12885-018-5117-8] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2018] [Accepted: 11/20/2018] [Indexed: 01/03/2023] Open
Abstract
Background Regulatory T cells (Treg) suppress cytotoxic T cell anti-tumoral immune responses and thereby promote tumor progression. Prevention of intratumoral Treg accumulation by inhibition of their migration to the tumor microenvironment is a promising therapeutic strategy. The aim of this study was to identify the role of the two major Treg-attracting chemokines CCL1 and CCL22 in human breast cancer. Methods One hundred ninety-nine tissue samples of patients with invasive breast cancer were stained for CCL1 and CCL22 by immunohistochemistry. Chemokine expression and tumor infiltration by regulatory T cells, determined by expression of the transcription factor FoxP3, were quantified and their correlation to clinical features was statistically analyzed. Results Both CCL1 and CCL22 were expressed in most breast cancer tissues. CCL1 was significantly over-expressed in invasive breast cancer as compared to normal breast tissue. CCL1, but surprisingly not CCL22, showed a significant correlation with the number of tumor-infiltrating FoxP3+ Treg (p< 0.001). High numbers of intratumoral CCL1 expressing cells were related to high grade tumors (G4) and a positive estrogen receptor (ER) status whereas high CCL22 expression was generally seen in lower grade tumors. The median survival of 88 patients with high intratumoral CCL1 expression was 37 months compared to 50 months for the 87 patients with low CCL1 levels, this trend was however not statistically significant. Conclusions We found a high expression of CCL1 in human breast cancer. CCL1 significantly correlated with the infiltration of immunosuppressive FoxP3+ Treg, that are known to negatively affect survival. Thus, CCL1 may serve as prognostic marker and novel therapeutic target in breast cancer.
Collapse
Affiliation(s)
- Benjamin Kuehnemuth
- Center of Integrated Protein Science Munich (CIPS-M), Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
| | - Ignazio Piseddu
- Center of Integrated Protein Science Munich (CIPS-M), Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
| | - Gabriela M Wiedemann
- Center of Integrated Protein Science Munich (CIPS-M), Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany.,Department of Medicine II, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
| | - Michael Lauseker
- Institut für medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Klinikum der Universität München, Munich, Germany
| | - Christina Kuhn
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Munich, Germany
| | - Simone Hofmann
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Munich, Germany
| | - Elisa Schmoeckel
- Pathologisches Institut, Medizinische Fakultät der Ludwig-Maximilians Universität München, Munich, Germany
| | - Stefan Endres
- Center of Integrated Protein Science Munich (CIPS-M), Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany
| | - Doris Mayr
- Pathologisches Institut, Medizinische Fakultät der Ludwig-Maximilians Universität München, Munich, Germany
| | - Udo Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Munich, Germany
| | - David Anz
- Center of Integrated Protein Science Munich (CIPS-M), Division of Clinical Pharmacology, Klinikum der Universität München, Munich, Germany. .,Medizinische Klinik und Poliklinik II, Klinikum der Universität München, Munich, Germany.
| |
Collapse
|
77
|
Hester A, Ritzer M, Kuhn C, Schmoeckel E, Mayr D, Kolben T, Dannecker C, Mahner S, Jeschke U, Kolben TM. The role of EP3-receptor expression in cervical dysplasia. J Cancer Res Clin Oncol 2018; 145:313-319. [PMID: 30402741 DOI: 10.1007/s00432-018-2785-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2018] [Accepted: 10/27/2018] [Indexed: 01/05/2023]
Abstract
PURPOSE Prostaglandin-mediated inflammatory reactions play a major role in different cancers. Prostaglandin E2-receptor 3 (EP3) expression correlates with FIGO stages in cervical cancer and has been shown to be an independent prognostic factor for overall survival. EP3 expression levels in cervical intraepithelial neoplasia (CIN) as the precursor lesion of cervical cancer are currently unknown. METHODS EP3 expression was analyzed by immunohistochemistry in 124 patient samples (CIN 1-3 and healthy controls) using the IR-scoring system. Expression levels were correlated with clinical outcome to assess for prognostic relevance in patients with CIN 2. Data analysis was performed using Kruskal-Wallis and Mann-Whitney U test. RESULTS EP3 expression levels significantly correlated with different grades of cervical dysplasia. Median EP3-IRS in healthy cervical tissue was 12 (n = 13) compared to 9 in CIN 1 (n = 38; p = 0.031 vs. healthy control), 6 in CIN 2 (n = 45; p < 0.001 vs. CIN 1) and 4 in CIN 3 (n = 28, p = 0.008 vs. CIN 2). The percentage of EP3 expressing cells in CIN 2 lesions was significantly lower in progressive than in regressive cases (mean percentage of EP3 positive cells in progress: 3.8%, n = 18; in regress: 9.3%, n = 20; p = 0.040). CONCLUSION EP3 expression significantly decreases with higher grades of cervical intraepithelial neoplasia-which is in line with published IR scores in cervical cancer patients-and seems to be a prognostic marker for regression or progression of CIN 2 lesions. Our findings support the importance of the prostanoid pathway in cervical cancer and could help to identify targets for future therapies.
Collapse
Affiliation(s)
- Anna Hester
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Manuel Ritzer
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Christina Kuhn
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Elisa Schmoeckel
- Department of Pathology, LMU Munich, Thalkirchnerstrasse 36, 80337, Munich, Germany
| | - Doris Mayr
- Department of Pathology, LMU Munich, Thalkirchnerstrasse 36, 80337, Munich, Germany
| | - Thomas Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Christian Dannecker
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.
| | - Theresa Maria Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany
| |
Collapse
|
78
|
Hester A, Ritzer M, Kuhn C, Schmoeckel E, Mayr D, Kolben T, Dobler F, Gallwas J, Dannecker C, Mahner S, Jeschke U, Kolben TM. Signifikante Abnahme der EP3-Expression mit zunehmendem Grad der zervikalen intraepithelialen Neoplasie. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- A Hester
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, LMU München, München, Deutschland
| | - M Ritzer
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, LMU München, München, Deutschland
| | - C Kuhn
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, LMU München, München, Deutschland
| | - E Schmoeckel
- Klinikum der LMU München, Institut für Pathologie, München, Deutschland
| | - D Mayr
- Klinikum der LMU München, Institut für Pathologie, München, Deutschland
| | - T Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, LMU München, München, Deutschland
| | - F Dobler
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, LMU München, München, Deutschland
| | - J Gallwas
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, LMU München, München, Deutschland
| | - C Dannecker
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, LMU München, München, Deutschland
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, LMU München, München, Deutschland
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, LMU München, München, Deutschland
| | - TM Kolben
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, LMU München, München, Deutschland
| |
Collapse
|
79
|
Kolben T, Karsten N, Kuhn C, Schmoeckel E, Hester A, Mahner S, Harbeck N, Jeschke U, Kolben TM. The impact of neoadjuvant chemotherapy on the tumour microenvironment and the expression of stem cell properties in breast cancer cells. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- T Kolben
- University Hospital, LMU, Department of Obstetrics and Gynecology, Munich, Deutschland
| | - N Karsten
- University Hospital, LMU, Department of Obstetrics and Gynecology, Munich, Deutschland
| | - C Kuhn
- University Hospital, LMU, Department of Obstetrics and Gynecology, Munich, Deutschland
| | - E Schmoeckel
- University Hospital, LMU, Department of Pathology, Munich, Deutschland
| | - A Hester
- University Hospital, LMU, Department of Obstetrics and Gynecology, Munich, Deutschland
| | - S Mahner
- University Hospital, LMU, Department of Obstetrics and Gynecology, Munich, Deutschland
| | - N Harbeck
- University Hospital, LMU, Department of Obstetrics and Gynecology, Munich, Deutschland
| | - U Jeschke
- University Hospital, LMU, Department of Obstetrics and Gynecology, Munich, Deutschland
| | - TM Kolben
- University Hospital, LMU, Department of Obstetrics and Gynecology, Munich, Deutschland
| |
Collapse
|
80
|
Kolben TM, Rogatsch E, Vattai A, Hester A, Kuhn C, Schmoeckel E, Mahner S, Jeschke U, Kolben T. PPARγ Expression Is Diminished in Macrophages of Recurrent Miscarriage Placentas. Int J Mol Sci 2018; 19:ijms19071872. [PMID: 29949879 PMCID: PMC6073463 DOI: 10.3390/ijms19071872] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2018] [Revised: 06/18/2018] [Accepted: 06/19/2018] [Indexed: 12/13/2022] Open
Abstract
PPARγ belongs to the group of nuclear receptors which is expressed in the trophoblast and together with other factors is responsible for the maintenance of pregnancy. Apart from that PPARγ is also a main factor for macrophage polarization. The aim of this study was to investigate the combined expression pattern and frequency of PPARγ under physiological circumstances and in spontaneous and recurrent miscarriages in the trophoblast and in maternal macrophages of the decidua. Human placental tissues of the first trimester (15 physiologic pregnancies, 15 spontaneous abortion and 16 recurrent miscarriage placentas) were analyzed for expression of the nuclear receptor PPARγ. Expression changes were evaluated by immunohistochemistry and real time PCR (RT-PCR) in trophoblast and in maternal macrophages of the decidua. Maternal macrophages were identified by double immunofluorescence using cluster of differentiation 68 (CD68) as marker for macrophages and further characterized regarding their M1/M2 polarization status. The intermediate villous trophoblast revealed a significantly lower PPARγ expression in spontaneous and recurrent abortion. Maternal macrophages express PPARγ. Their number is significantly enhanced in the decidua of spontaneous miscarriages whereas in recurrent miscarriages maternal macrophages seem to express PPARγ only in very few cases. PPARγ is associated with an M2 polarization state that is common for decidual macrophages. The lack of PPARγ in recurrent miscarriage decidual macrophages seems to be associated with a specific inflammatory response against the fetus.
Collapse
Affiliation(s)
- Theresa Maria Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany.
| | - Elisabeth Rogatsch
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany.
| | - Aurelia Vattai
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany.
| | - Anna Hester
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany.
| | - Christina Kuhn
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany.
| | - Elisa Schmoeckel
- Department of Pathology, LMU Munich, Marchioninistr. 27, 81377 Munich, Germany.
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany.
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany.
| | - Thomas Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany.
| |
Collapse
|
81
|
Kahlert S, Kolben TM, Schmoeckel E, Czogalla B, Hester A, Degenhardt T, Kempf C, Mahner S, Harbeck N, Kolben T. Prognostic impact of residual disease in simultaneous additional excision specimens after one-step breast conserving therapy with negative final margin status in primary breast cancer. Eur J Surg Oncol 2018; 44:1318-1323. [PMID: 30041974 DOI: 10.1016/j.ejso.2018.06.014] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2018] [Revised: 06/06/2018] [Accepted: 06/18/2018] [Indexed: 12/22/2022] Open
Abstract
PURPOSE The purpose of this study was the evaluation of risk factors for local recurrence after breast conserving surgery (BCS) with special focus on the impact of residual disease in specimens of simultaneous additional excisions (AE) from the tumor cavity on patients' outcome in patients with negative final margin status after one-step BCS. METHODS This study was designed as a single center retrospective cohort study. Patients with primary non-metastatic breast cancer treated by one-step BCS with pathologically confirmed negative resection status between 1990 and 2006 were included. Ipsilateral breast tumor recurrence (IBTR) and overall survival (OS) were evaluated by Kaplan-Meier-estimates. A multivariate Cox proportional hazards regression model was used to identify potential independent prognostic factors associated with the risk of IBTR. RESULTS A total of 1081 patients were included in this analysis. Simultaneous additional excisions were performed in 79.4% of patients (tumor positive: 12.2%). Median follow-up after primary diagnosis was 124 months. The IBTR rate after 15 years was significantly higher in the group with tumor positive AE (no AE (10.2%) vs. AE tumor positive (27.5%) p = 0.002; AE tumor negative (14.0%) vs. AE tumor positive (27.5%) p = 0.008). The OS rate did not differ significantly between groups. Multivariate analysis revealed residual cancer in AE being associated with a significantly increased relative risk of IBTR of 2.0 (p = 0.014). CONCLUSION In the current analysis residual disease in simultaneous additional excisions was associated with an increased risk for IBTR despite negative final margin status. This should be considered in the overall therapeutic concept.
Collapse
Affiliation(s)
- Steffen Kahlert
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 15, 81377 Munich, Germany
| | - Theresa M Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 15, 81377 Munich, Germany
| | - Elisa Schmoeckel
- Department of Pathology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany
| | - Bastian Czogalla
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 15, 81377 Munich, Germany
| | - Anna Hester
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 15, 81377 Munich, Germany
| | - Tom Degenhardt
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 15, 81377 Munich, Germany
| | - Cordula Kempf
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 15, 81377 Munich, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 15, 81377 Munich, Germany
| | - Nadia Harbeck
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 15, 81377 Munich, Germany
| | - Thomas Kolben
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 15, 81377 Munich, Germany.
| |
Collapse
|
82
|
Schulz H, Kuhn C, Hofmann S, Mayr D, Mahner S, Jeschke U, Schmoeckel E. Overall Survival of Ovarian Cancer Patients Is Determined by Expression of Galectins-8 and -9. Int J Mol Sci 2018; 19:ijms19010323. [PMID: 29361803 PMCID: PMC5796266 DOI: 10.3390/ijms19010323] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2017] [Revised: 01/16/2018] [Accepted: 01/18/2018] [Indexed: 12/24/2022] Open
Abstract
The evaluation of new prognostic factors that can be targeted in ovarian cancer diagnosis and therapy is of the utmost importance. Galectins are a family of carbohydrate binding proteins with various implications in cancer biology. In this study, the presence of galectin (Gal)-8 and -9 was investigated in 156 ovarian cancer samples using immunohistochemistry (IHC). Staining was evaluated using semi-quantitative immunoreactivity (IR) scores and correlated to clinical and pathological data. Different types of galectin expression were compared with respect to disease-free survival (DFS) and overall survival (OS). Gal-8 served as a new positive prognostic factor for the OS and DFS of ovarian cancer patients. Gal-9 expression determined the DFS and OS of ovarian cancer patients in two opposing ways—moderate Gal-9 expression was correlated with a reduced outcome as compared to Gal-9 negative cases, while patients with high Gal-9 expression showed the best outcome.
Collapse
Affiliation(s)
- Heiko Schulz
- LMU Munich, University Hospital, Department of Obstetrics and Gynecology, Maistrasse 11, 80337 Munich, Germany.
| | - Christina Kuhn
- LMU Munich, University Hospital, Department of Obstetrics and Gynecology, Maistrasse 11, 80337 Munich, Germany.
| | - Simone Hofmann
- LMU Munich, University Hospital, Department of Obstetrics and Gynecology, Maistrasse 11, 80337 Munich, Germany.
| | - Doris Mayr
- LMU Munich, Department of Pathology, Ludwig Maximilians University of Munich, Thalkirchner Str. 142, 80337 Munich, Germany.
| | - Sven Mahner
- LMU Munich, University Hospital, Department of Obstetrics and Gynecology, Maistrasse 11, 80337 Munich, Germany.
| | - Udo Jeschke
- LMU Munich, University Hospital, Department of Obstetrics and Gynecology, Maistrasse 11, 80337 Munich, Germany.
| | - Elisa Schmoeckel
- LMU Munich, Department of Pathology, Ludwig Maximilians University of Munich, Thalkirchner Str. 142, 80337 Munich, Germany.
| |
Collapse
|
83
|
Schmoeckel E, Kirchner T, Mayr D. SATB2 is a supportive marker for the differentiation of a primary mucinous tumor of the ovary and an ovarian metastasis of a low-grade appendiceal mucinous neoplasm (LAMN): A series of seven cases. Pathol Res Pract 2017; 214:426-430. [PMID: 29487003 DOI: 10.1016/j.prp.2017.12.008] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/03/2017] [Revised: 12/07/2017] [Accepted: 12/11/2017] [Indexed: 11/19/2022]
Abstract
The differentiation between a primary mucinous ovarian neoplasm and an extra-ovarian metastasis in the ovary is often challenging in the histopathologic practice. Among various ovarian metastases from the gastro-intestinal tract the low-grade appendiceal mucinous neoplasm (LAMN) is an important differential diagnosis to consider particularly in case of pseudomyxoma peritonei. A newly recognized marker in the routine diagnostic of a mucinous neoplasm in the ovary is SATB2 (Special AT-rich sequence-binding protein 2). The expression of SATB2 is, within cells of epithelial lineages, mainly restricted to the lower gastro-intestinal tract, indicating colorectal or appendiceal cancer origin. We report seven cases of LAMN, which clinically became apparent due to ovarian metastases in context of pseudomyxoma peritonei or at least small foci of peritoneal tumor spread. An immunohistochemical marker-panel including SATB2, CDX2, CK20, CK7, PAX8, ER and PR revealed a strong expression of SATB2 in all seven cases. On the contrary SATB2-negativity could be demonstrated in the 40 cases of mucinous borderline tumors and primary mucinous carcinomas of the ovary. The histopathologic tentative diagnosis of an ovarian metastasis of LAMN could be confirmed in the findings of the Appendix in six of seven cases. This report supports SATB2 as an additional diagnostic marker for the diagnosis of an ovarian manifestation of LAMN.
Collapse
Affiliation(s)
- Elisa Schmoeckel
- Institute of Pathology, Faculty of Medicine, LMU Munich, Germany.
| | - Thomas Kirchner
- Institute of Pathology, Faculty of Medicine, LMU Munich, Germany
| | - Doris Mayr
- Institute of Pathology, Faculty of Medicine, LMU Munich, Germany
| |
Collapse
|
84
|
Kolben T, Jeschke U, Reimer T, Karsten N, Schmoeckel E, Semmlinger A, Mahner S, Harbeck N, Kolben TM. Induction of apoptosis in breast cancer cells in vitro by Fas ligand reverse signaling. J Cancer Res Clin Oncol 2017; 144:249-256. [PMID: 29185091 DOI: 10.1007/s00432-017-2551-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2017] [Accepted: 11/23/2017] [Indexed: 02/02/2023]
Abstract
PURPOSE The Fas-antigen is a cell surface receptor that transduces apoptotic signals into cells. The purpose of this study was to evaluate FasL expression in breast cancer and to elucidate the role of its signaling in different breast cancer cell lines. METHODS T47D and MCF7 cells were used and cultured in Dulbecco's modified Eagle's medium. FasL translocation to the membrane was achieved by culturing the cells in the presence of human interferon-γ (IFNγ). Translocation was detected by immunofluorescence. The ability of a Fas:Fc fusion protein to trigger apoptosis in these cells was investigated by cell death detection ELISA. After incubation with IFNγ for 4 h and 18 h, apoptosis was assessed in response to treatment with Fas:Fc. RESULTS Immunofluorescence revealed that the used cell lines were positive for FasL which was increased and changed to more membrane-bound FasL expression after IFNγ stimulation. After stimulation with 50 IU/ml IFNγ, Fas:Fc significantly increased MCF7 apoptosis (1.39 ± 0.06-fold, p = 0.0004) after 18 h. After stimulation with 100 IU/ml, Fas:Fc significantly increased apoptosis both after 4 h (1.49 ± 0.15-fold, p = 0.018) and 18 h (1.30 ± 0.06-fold, p = 0.013). In T47D cells this effect was seen after 4 h of stimulation with 50 IU/ml and addition of Fas:Fc (1.6 ± 0.08-fold, p = 0.03). CONCLUSION Membrane-bound FasL expression could be induced by IFNγ in a breast cancer cell model. More importantly, in the presence of IFNγ the Fas:Fc fusion protein was able to transmit pro-apoptotic signals to T47D and MCF7 cells, significantly inducing apoptosis. The current findings support further in vivo studies regarding FasL activation as a potential target for therapeutic intervention in breast cancer.
Collapse
Affiliation(s)
- Thomas Kolben
- Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-University Munich, Marchioninistr. 15, 81377, Munich, Germany.
| | - Udo Jeschke
- Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-University Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Toralf Reimer
- Department of Obstetrics and Gynecology, University of Rostock, Suedring 81, 18059, Rostock, Germany
| | - Nora Karsten
- Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-University Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Elisa Schmoeckel
- Department of Pathology, Ludwig-Maximilians-University Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Anna Semmlinger
- Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-University Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-University Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Nadia Harbeck
- Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-University Munich, Marchioninistr. 15, 81377, Munich, Germany
| | - Theresa M Kolben
- Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-University Munich, Marchioninistr. 15, 81377, Munich, Germany
| |
Collapse
|
85
|
Schmoeckel E, Odai-Afotey AA, Schleiβheimer M, Rottmann M, Flesken-Nikitin A, Ellenson LH, Kirchner T, Mayr D, Nikitin AY. LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions. Mod Pathol 2017; 30:1241-1250. [PMID: 28664938 PMCID: PMC5604248 DOI: 10.1038/modpathol.2017.53] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2017] [Revised: 04/10/2017] [Accepted: 04/19/2017] [Indexed: 12/14/2022]
Abstract
Recently it has been reported that serous tubal intraepithelial carcinoma (STIC), the likely precursor of ovarian/extra-uterine high-grade serous carcinoma, are frequently located in the vicinity of tubal-peritoneal junctions, consistent with the cancer-prone features of many epithelial transitional regions. To test if p53 (aka TP53)-signatures and secretory cell outgrowths (SCOUTs) also localize to tubal-peritoneal junctions, we examined these lesions in the fallopian tubes of patients undergoing salpingo-oophorectomy for sporadic high-grade serous carcinomas or as a prophylactic procedure for carriers of familial BRCA1 or 2 mutations. STICs were located closest to the tubal-peritoneal junctions with an average distance of 1.31 mm, while SCOUTs were not detected in the fimbriated end of the fallopian tube. As many epithelial transitional regions contain stem cells, we also determined the expression of stem cell markers in the normal fallopian tube, tubal intraepithelial lesions and high-grade serous carcinomas. Of those, LEF1 was consistently expressed in the tubal-peritoneal junctions and all lesions, independent of p53 status. All SCOUTs demonstrated strong nuclear expression of β-catenin consistent with the LEF1 participation in the canonical WNT pathway. However, β-catenin was preferentially located in the cytoplasm of cells comprising STICs and p53 signatures, suggesting WNT-independent function of LEF1 in those lesions. Both frequency of LEF1 expression and β-catenin nuclear expression correlated with the worst 5-year patient survival, supporting important role of both proteins in high-grade serous carcinoma. Taken together, our findings suggest the existence of stem cell niche within the tubal-peritoneal junctions. Furthermore, they support the notion that the pathogenesis of SCOUTs is distinct from that of STICs and p53 signatures. The location and discrete patterns of LEF1 and β-catenin expression may serve as highly sensitive and reliable ancillary markers for the detection and differential diagnosis of tubal intraepithelial lesions.
Collapse
Affiliation(s)
- Elisa Schmoeckel
- Institute of Pathology, Ludwig Maximilians University, Munich,
Germany
| | - Ashley A. Odai-Afotey
- Department of Biomedical Sciences and Cornell Stem Cell Program,
Cornell University, Ithaca, New York, USA
| | | | - Miriam Rottmann
- Institute of Medical Information Processing, Biometry und
Epidemiology, Ludwig Maximilians University, Munich, Germany
| | - Andrea Flesken-Nikitin
- Department of Biomedical Sciences and Cornell Stem Cell Program,
Cornell University, Ithaca, New York, USA
| | - Lora H. Ellenson
- Department of Pathology and Laboratory Medicine, Weill Cornell
Medicine, New York, New York
| | - Thomas Kirchner
- Institute of Pathology, Ludwig Maximilians University, Munich,
Germany
| | - Doris Mayr
- Institute of Pathology, Ludwig Maximilians University, Munich,
Germany
| | - Alexander Yu. Nikitin
- Department of Biomedical Sciences and Cornell Stem Cell Program,
Cornell University, Ithaca, New York, USA
| |
Collapse
|
86
|
Schulz H, Schmoeckel E, Kuhn C, Hofmann S, Mayr D, Mahner S, Jeschke U. Galectins-1, -3, and -7 Are Prognostic Markers for Survival of Ovarian Cancer Patients. Int J Mol Sci 2017; 18:ijms18061230. [PMID: 28594391 PMCID: PMC5486053 DOI: 10.3390/ijms18061230] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2017] [Revised: 06/01/2017] [Accepted: 06/05/2017] [Indexed: 02/01/2023] Open
Abstract
There is a tremendous need for developing new useful prognostic factors in ovarian cancer. Galectins are a family of carbohydrate binding proteins which have been suggested to serve as prognostic factors for various cancer types. In this study, the presence of Galectin-1, -3, and -7 was investigated in 156 ovarian cancer specimens by immunochemical staining. Staining was evaluated in the cytoplasm and nucleus of cancer cells as well as the peritumoral stroma using a semi quantitative score (Remmele (IR) score). Patients’ overall survival was compared between different groups of Galectin expression. Galectin (Gal)-1 and -3 staining was observed in the peritumoral stroma as well as the nucleus and cytoplasm of tumor cells, while Gal-7 was only present in the cytoplasm of tumor cells. Patients with Gal-1 expression in the cytoplasm or high Gal-1 expression in the peritumoral stroma showed reduced overall survival. Nuclear Gal-3 staining correlated with a better outcome. We observed a significantly reduced overall survival for cases with high Gal-7 expression and a better survival for Gal-7 negative cases, when compared to cases with low expression of Gal-7. We were able to show that both tumor and stroma staining of Gal-1 could serve as negative prognostic factors for ovarian cancer. We were able to confirm cytoplasmic Gal-7 as a negative prognostic factor. Gal-3 staining in the nucleus could be a new positive prognosticator for ovarian cancer.
Collapse
Affiliation(s)
- Heiko Schulz
- Department of Gynaecology and Obstetrics, Ludwig-Maximilians University of Munich, Campus Großhadern: Marchioninistr. 15, 81377 Munich and Campus Innenstadt: Maistr. 11, Munich 80337, Germany.
| | - Elisa Schmoeckel
- LMU Munich, Department of Pathology, Ludwig Maximilians University of Munich, Thalkirchner Str. 142, Munich 80337, Germany.
| | - Christina Kuhn
- Department of Gynaecology and Obstetrics, Ludwig-Maximilians University of Munich, Campus Großhadern: Marchioninistr. 15, 81377 Munich and Campus Innenstadt: Maistr. 11, Munich 80337, Germany.
| | - Simone Hofmann
- Department of Gynaecology and Obstetrics, Ludwig-Maximilians University of Munich, Campus Großhadern: Marchioninistr. 15, 81377 Munich and Campus Innenstadt: Maistr. 11, Munich 80337, Germany.
| | - Doris Mayr
- LMU Munich, Department of Pathology, Ludwig Maximilians University of Munich, Thalkirchner Str. 142, Munich 80337, Germany.
| | - Sven Mahner
- Department of Gynaecology and Obstetrics, Ludwig-Maximilians University of Munich, Campus Großhadern: Marchioninistr. 15, 81377 Munich and Campus Innenstadt: Maistr. 11, Munich 80337, Germany.
| | - Udo Jeschke
- Department of Gynaecology and Obstetrics, Ludwig-Maximilians University of Munich, Campus Großhadern: Marchioninistr. 15, 81377 Munich and Campus Innenstadt: Maistr. 11, Munich 80337, Germany.
| |
Collapse
|
87
|
Semmlinger A, Schoenfeldt V, Schmoeckel E, Mahner S, Jeschke U, Ditsch N. Prognostische Relevanz des EP3-Rezeptors bei sporadischem Brustkrebs. Geburtshilfe Frauenheilkd 2017. [DOI: 10.1055/s-0037-1602357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Affiliation(s)
- A Semmlinger
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe LMU München, Campus Großhadern, München, Deutschland
| | - V Schoenfeldt
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe LMU München, Campus Innenstadt, München, Deutschland
| | - E Schmoeckel
- Institut für Pathologie LMU München, München, Deutschland
| | - S Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe LMU München, Campus Großhadern, München, Deutschland
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe LMU München, Campus Innenstadt, München, Deutschland
| | - U Jeschke
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe LMU München, Campus Großhadern, München, Deutschland
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe LMU München, Campus Innenstadt, München, Deutschland
| | - N Ditsch
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe LMU München, Campus Großhadern, München, Deutschland
| |
Collapse
|
88
|
Schulz H, Kuhn C, Schmoeckel E, Mayr D, Mahner S, Jeschke U. Evaluation von Galektin-1, -3 & -7 als prognostische Faktoren im Ovarialkarzinom. Geburtshilfe Frauenheilkd 2017. [DOI: 10.1055/s-0037-1602362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Affiliation(s)
- H Schulz
- LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München, Deutschland
| | - C Kuhn
- LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München, Deutschland
| | - E Schmoeckel
- LMU München, Pathologisches Institut, München, Deutschland
| | - D Mayr
- LMU München, Pathologisches Institut, München, Deutschland
| | - S Mahner
- LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München, Deutschland
| | - U Jeschke
- LMU München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München, Deutschland
| |
Collapse
|
89
|
Semmlinger A, von Schönfeldt V, Wolf V, Schmoeckel E, Mayr D, Meuter A, Mahner S, Jeschke U, Ditsch N. Abstract P2-05-23: EP3-receptor expression is a prognostic marker for overall survival and progression-free survival in sporadic breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-05-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Aim: Prostaglandins are tissue hormones with a variety of biological effects and are mainly associated with infection and inflammation. However, elevated prostaglandin synthesis, especially of prostaglandin E2 (PGE2) caused by overexpression of cyclooxygenase-2 (COX-2), has also been associated with the development and progression of different kinds of cancer. Clinical trials have shown the potential of non-steroidal anti-inflammatory drugs or specific COX-2 inhibitors (coxibs) in prevention and treatment of malignant disease, as they reduce prostaglandin levels via inhibition of COX-2. Unfortunately, the clinical use of these drugs is limited due to their various side effects. PGE2 exerts its effects by signaling through four specific membrane-bound receptors, the EP-receptors 1-4. In recent research, the relevance of EP-receptors in carcinogenesis is investigated in the attempt to find a more specific target for the reduction of prostaglandin-effects without inducing side effects. This study evaluates the expression of EP3-receptor on breast cancer tissue and its correlation to progression and survival
Material and methods: A total of 277 sporadic breast cancer samples without primary distant metastases were immunohistochemically analyzed for EP3-receptor expression. Tissue samples were stained with primary anti-EP3 antibodies (monoclonal rabbit IgG). EP3-receptor-expression was quantified by the semi-quantitative immunoreactivity score (IRS); samples with an IRS ≥ 2 were scored as EP3 positive. Statistical analyses were performed with SPSS software using chi-squared test as well as Kaplan-Meier-estimates and Cox regression for survival analyses.
Results: EP3-receptor was expressed in 71.1 % of all cases. EP3-receptor expression did not correlate with clinicopathological parameters such as tumor size or lymph node status at primary diagnosis or with the expression of other immunohistochemical markers (estrogen and progesterone receptor, Her2). Distant metastasis occurred in 49.1 % of EP3 negative cases but only in 32.8 % of EP3 positive cases in an observation period of up to ten years (p = 0.03). EP3 receptor positive cases also showed significantly improved progression-free survival rates (overall [p = 0.01], ten years [p = 0.002] and five years [p = 0.04]). Furthermore, EP3-receptor positivity was associated with an improved overall survival rate (p = 0.002) and ten years survival rate (p = 0.001), whereas short-time survival rate (five years) did not differ between both EP3-groups (p = 0.10). In a multivariate analysis comparing all factors with significant influence in univariate testing, EP3-receptor could be confirmed as an independent factor.
Discussion: Our results show that EP3-receptor positivity is a relevant prognostic factor in sporadic breast cancer. Its correlation with a favorable course of disease is especially interesting as EP3 is known to regulate uPA, a well-known parameter which is – on the contrary - associated with unfavorable survival in breast cancer. Therefore, ongoing studies by our group aim to examine the correlation of EP3-receptor to the uPA/PAI1-pathway and to evaluate the possibility to target EP3-receptor in future anti-tumor therapy in breast cancer.
Citation Format: Semmlinger A, von Schönfeldt V, Wolf V, Schmoeckel E, Mayr D, Meuter A, Mahner S, Jeschke U, Ditsch N. EP3-receptor expression is a prognostic marker for overall survival and progression-free survival in sporadic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-05-23.
Collapse
Affiliation(s)
| | | | - V Wolf
- LMU Munich, Munich, Bavaria, Germany
| | | | - D Mayr
- LMU Munich, Munich, Bavaria, Germany
| | - A Meuter
- LMU Munich, Munich, Bavaria, Germany
| | - S Mahner
- LMU Munich, Munich, Bavaria, Germany
| | - U Jeschke
- LMU Munich, Munich, Bavaria, Germany
| | - N Ditsch
- LMU Munich, Munich, Bavaria, Germany
| |
Collapse
|
90
|
Semmlinger A, Schönfeldt VV, Wolf V, Schmoeckel E, Mayr D, Mahner S, Jeschke U, Ditsch N. Prognostic relevance of EP3-receptor expression in sporadic breast cancer tissue. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
91
|
Kolben TM, Kraft F, Kolben T, Dannecker C, Goess C, Schmoeckel E, Mayr D, Mahner S, Jeschke U. Expression von Sialyl Lewis a, Sialyl Lewis x, Lewis y, Galectin 3, Galectin 7, Stahmin 1 sowie p16 bei zervikalen intraepithelialen Neoplasien. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592717] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
92
|
Kolben TM, Kraft F, Kolben T, Goess C, Semmlinger A, Dannecker C, Schmoeckel E, Mayr D, Sommer NN, Mahner S, Jeschke U. Expression of Sialyl Lewis a, Sialyl Lewis x, Lewis y, Gal-3, Gal-7, STMN1 and p16 in cervical dysplasia. Future Oncol 2016; 13:145-157. [PMID: 27646625 DOI: 10.2217/fon-2016-0259] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
AIM Cervical intraepithelial neoplasia (CIN) is commonly divided into three grades. Guidelines increasingly recommend surgery only in CIN 3 lesions. We investigated markers to evaluate differences in CIN 2 and 3 lesions as well as possible predictors for regression/progression in CIN 2 lesions. MATERIALS & METHODS Biopsies (n = 128) of healthy cervical tissue and CIN 1-3 were stained for Sialyl Lewis a, Sialyl Lewis x, Lewis y, Gal-3, Gal-7, STMN1 and p16. RESULTS We observed significant differences between CIN 2 and 3 lesions for Sialyl Lewis a, Sialyl Lewis x, Gal-3, Gal-7, STMN1 and p16. Expression of Sialyl Lewis a was significantly higher in CIN 2 patients who progressed during follow-up. CONCLUSION Significant differences in marker expression support the differentiation of CIN 2 and 3. Lewis a may help to predict progression/regression in CIN 2 patients.
Collapse
Affiliation(s)
- Theresa M Kolben
- Department for Obstetrics & Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Marchioninistr. 15, 81377, Munich, Germany
| | - Franziska Kraft
- Department for Obstetrics & Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Marchioninistr. 15, 81377, Munich, Germany
| | - Thomas Kolben
- Department for Obstetrics & Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Marchioninistr. 15, 81377, Munich, Germany
| | - Christine Goess
- Department for Obstetrics & Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Marchioninistr. 15, 81377, Munich, Germany
| | - Anna Semmlinger
- Department for Obstetrics & Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Marchioninistr. 15, 81377, Munich, Germany
| | - Christian Dannecker
- Department for Obstetrics & Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Marchioninistr. 15, 81377, Munich, Germany
| | - Elisa Schmoeckel
- Department of Pathology, University Hospital of Munich, Ludwig-Maximilians-University, Marchioninistr. 27, 81377, Munich, Germany
| | - Doris Mayr
- Department of Pathology, University Hospital of Munich, Ludwig-Maximilians-University, Marchioninistr. 27, 81377, Munich, Germany
| | - Nora N Sommer
- Institute for Clinical Radiology, University Hospital of Munich, Ludwig-Maximilians-University, Marchioninistr. 15, 81377, Munich, Germany
| | - Sven Mahner
- Department for Obstetrics & Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Marchioninistr. 15, 81377, Munich, Germany
| | - Udo Jeschke
- Department for Obstetrics & Gynecology, University Hospital of Munich, Ludwig-Maximilians-University, Marchioninistr. 15, 81377, Munich, Germany
| |
Collapse
|
93
|
Foerster F, Braig S, Moser C, Kubisch R, Busse J, Wagner E, Schmoeckel E, Mayr D, Schmitt S, Huettel S, Zischka H, Mueller R, Vollmar AM. Targeting the actin cytoskeleton: selective antitumor action via trapping PKCɛ. Cell Death Dis 2014; 5:e1398. [PMID: 25165884 PMCID: PMC4454332 DOI: 10.1038/cddis.2014.363] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2014] [Revised: 07/14/2014] [Accepted: 07/16/2014] [Indexed: 12/18/2022]
Abstract
Targeting the actin cytoskeleton (CSK) of cancer cells offers a valuable strategy in cancer therapy. There are a number of natural compounds that interfere with the actin CSK, but the mode of their cytotoxic action and, moreover, their tumor-specific mechanisms are quite elusive. We used the myxobacterial compound Chondramide as a tool to first elucidate the mechanisms of cytotoxicity of actin targeting in breast cancer cells (MCF7, MDA-MB-231). Chondramide inhibits cellular actin filament dynamics shown by a fluorescence-based analysis (fluorescence recovery after photobleaching (FRAP)) and leads to apoptosis characterized by phosphatidylserine exposure, release of cytochrome C from mitochondria and finally activation of caspases. Chondramide enhances the occurrence of mitochondrial permeability transition (MPT) by affecting known MPT modulators: Hexokinase II bound to the voltage-dependent anion channel (VDAC) translocated from the outer mitochondrial membrane to the cytosol and the proapoptotic protein Bad were recruited to the mitochondria. Importantly, protein kinase C-ɛ (PKCɛ), a prosurvival kinase possessing an actin-binding site and known to regulate the hexokinase/VDAC interaction as well as Bad phosphorylation was identified as the link between actin CSK and apoptosis induction. PKCɛ, which was found overexpressed in breast cancer cells, accumulated in actin bundles induced by Chondramide and lost its activity. Our second goal was to characterize the potential tumor-specific action of actin-binding agents. As the nontumor breast epithelial cell line MCF-10A in fact shows resistance to Chondramide-induced apoptosis and notably express low level of PKCɛ, we suggest that trapping PKCɛ via Chondramide-induced actin hyperpolymerization displays tumor cell specificity. Our work provides a link between targeting the ubiquitously occurring actin CSK and selective inhibition of pro-tumorigenic PKCɛ, thus setting the stage for actin-stabilizing agents as innovative cancer drugs. This is moreover supported by the in vivo efficacy of Chondramide triggered by abrogation of PKCɛ signaling shown in a xenograft breast cancer model.
Collapse
Affiliation(s)
- F Foerster
- Department of Pharmacy, Pharmaceutical Biology, University of Munich, Munich, Germany
| | - S Braig
- Department of Pharmacy, Pharmaceutical Biology, University of Munich, Munich, Germany
| | - C Moser
- Department of Pharmacy, Pharmaceutical Biology, University of Munich, Munich, Germany
| | - R Kubisch
- Department of Pharmacy, Pharmaceutical Biology, University of Munich, Munich, Germany
| | - J Busse
- Department of Pharmacy, Pharmaceutical Biotechnology, University of Munich, Munich, Germany
| | - E Wagner
- Department of Pharmacy, Pharmaceutical Biotechnology, University of Munich, Munich, Germany
| | - E Schmoeckel
- Institute of Pathology, University of Munich, Munich, Germany
| | - D Mayr
- Institute of Pathology, University of Munich, Munich, Germany
| | - S Schmitt
- Institute for Molecular Toxicology and Pharmacology, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg, Germany
| | - S Huettel
- Institute of Pathology, University of Munich, Munich, Germany
| | - H Zischka
- Institute for Molecular Toxicology and Pharmacology, Helmholtz Centre Munich, German Research Center for Environmental Health, Neuherberg, Germany
| | - R Mueller
- Helmholtz Institute for Pharmaceutical Research Saarland, Helmholtz Centre for Infection Research and Department of Pharmaceutical Biotechnology, Saarland University, Saarbrücken, Germany
| | - A M Vollmar
- Department of Pharmacy, Pharmaceutical Biology, University of Munich, Munich, Germany
| |
Collapse
|
94
|
Soleimani M, Barone S, Xu J, Zahedi K, Pavlov T, Levchenko V, Ilatovskaya D, Palygin O, Staruschenko A, Lee CT, Ng HY, Lee YT, Lien YH, Lai LW, Chiou T, Fischereder M, Michalke B, Schmoeckel E, Habicht A, Szabados B, Nelson PJ, Stangl M, Colombaro V, Decleves AE, Jadot I, Voisin V, Giordano L, Habsch I, Flamion B, Caron N. WATER AND SALT. Nephrol Dial Transplant 2014. [DOI: 10.1093/ndt/gfu113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|